Stockreport

Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference [Yahoo! Finance]

Lexeo Therapeutics, Inc.  (LXEO) 
PDF biodistribution preclinically and validated clinically, enabling meaningful cardiac delivery at relatively low doses with a favorable safety profile. Lead FA candidate [Read more]